Milpitas, CA, United States of America

Robert E Myrback

This inventor holds 1 USPTO granted patent. Top assignee: Alza Corporation. Active years: 1998.


% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 7(Granted Patents)


Company Filing History:


Years Active: 1998

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Robert E Myrback

Introduction

Robert E Myrback is a notable inventor based in Milpitas, CA (US). He has made significant contributions to the field of pharmaceuticals, particularly in enhancing the absorption of therapeutic polypeptides. His work has implications for improving drug delivery systems, which can lead to better patient outcomes.

Latest Patents

Robert E Myrback holds a patent for "Permeation enhancer compositions for increased absorption of therapeutic." This invention focuses on a pharmaceutical formulation that combines a therapeutic polypeptide with a permeation-enhancing mixture of sodium 3-nitrobenzoate and an oil. The goal of this formulation is to enhance the absorption of the polypeptide through the gastrointestinal tract, especially the colon, after oral administration.

Career Highlights

Throughout his career, Robert has been associated with Alza Corporation, a company known for its innovative drug delivery systems. His work at Alza has allowed him to explore and develop new methods for improving the efficacy of therapeutic agents.

Collaborations

Robert E Myrback has collaborated with notable colleagues, including Heechung Yang and Deborah A Fox. These collaborations have contributed to the advancement of research in pharmaceutical formulations and drug delivery technologies.

Conclusion

Robert E Myrback's contributions to the field of pharmaceuticals through his innovative patent demonstrate his commitment to enhancing therapeutic efficacy. His work continues to influence the development of more effective drug delivery systems.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…